Web results:
If you experience Paxlovid rebound, it’s important to isolate yourself to avoid getting others sick. Stay home for at least 5 days. After that, continue to wear a mask around others for another 5 days. Your first day of Paxlovid rebound symptoms would be considered “Day 0.”.
The treatment consists of two drugs — nirmatrelvir and ritonavir — which work together to suppress SARS-CoV-2 by blocking an enzyme that allows the virus to replicate in the body. It is easier to take at home compared to drugs like Remdesivir, which require intravenous injection.
For more information about viral rebound and the recurrence of COVID-19 symptoms, refer to the NIH COVID-19 Treatment Guidelines: Ritonavir-Boosted Nirmatrelvir (Paxlovid). Paxlovid Fact Sheet for Healthcare Providers FAQs on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19 Paxlovid Eligibility Checklist
Paxlovid treatment helps prevent hospitalization and death due to COVID-19. COVID-19 rebound has been reported to occur between 2 and 8 days after initial recovery and is characterized by a recurrence of COVID-19 symptoms or a new positive viral test after having tested negative.
If your COVID-19 symptoms return after you finish Paxlovid, you should isolate yourself again for at least five days. After five days, if you have gone a full day without any signs of a fever, you can leave isolation. However, you should still wear a mask for 10 days after your symptoms started again.
The treatment consists of three different drugs, and if the patient doesn’t get a high enough dose of nirmatrelvir—the part of Paxlovid that targets COVID-19 enzymes—pockets of SARS-CoV-2 may survive. Those remaining traces may cause viral levels to climb back up days after treatment stops.
It’s also unclear how often rebound occurs after treatment for COVID-19. Some research suggests it happens in about 3 to 5 percent of people who take Paxlovid or molnupiravir, another oral antiviral treatment for COVID. The good news: When rebound does happen, it tends to be “very mild,” Lawrence says.